在获得的向治疗耐药性和对免疫疗法耐药性的影响中对瘤免疫微环境的免疫调节
1Department of Medical Education, Taipei Veterans General Hospital, Taipei 112201, Taiwan.
Translational oncology
|March 9, 2025
概括
分子向疗法可以最初提高抗癌免疫力,但耐药性会导致免疫变化,阻碍免疫疗法在固体瘤中的有效性.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症治疗 癌症治疗
背景情况:
- 分子向疗法和免疫疗法已经改变了癌症治疗.
- 结合这些治疗的最佳顺序仍在研究中.
- 向疗法可以最初刺激抗瘤免疫反应.
研究的目的:
- 审查与针对性癌症疗法耐药性相关的免疫调节效应.
- 为了突出这些免疫变化对随后的免疫疗法所带来的挑战.
- 专注于固体瘤.
主要方法:
- 对针对性治疗耐药性和瘤免疫微环境研究的文献综述.
- 分析瘤免疫微环境中的动态变化.
- 综合有关免疫疗法疗效和针对性治疗后耐药性的研究结果.
主要成果:
- 对向疗法的耐药性与瘤免疫微环境的显著变化有关.
- 这些变化可以促进瘤的进展和免疫规避.
- 由此产生的免疫场景往往预测免疫疗法反应的降低.
结论:
- 了解针对性治疗耐药性的免疫调节后果至关重要.
- 需要克服抵抗诱导的免疫抑制的策略,以改善免疫治疗的结果.
- 优化治疗序列需要考虑这些动态的瘤免疫相互作用.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.1K
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
3.3K
相关概念视频
Tumor Immunotherapy
457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cytotoxic T Cells-mediated Immune Response
825
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
825
